Healthcare Analyst Yi Chen, along with Chief Medical Officer Scholl discuss the company’s reported data from the Phase 3 DRAGON trial of Tinlarebant in adolescent patients with Stargardt disease on a conference call to be held on December 17 at 3 pm hosted by H.C. Wainwright. Webcast Link
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio Prices $350 Million ADS Offering to Boost Drug Development
- Belite Bio price target raised to $200 from $140 at Maxim
- Belite Bio 2.273M share Spot Secondary priced at $154.00
- Mizuho upgrades Belite to Buy on ‘impressive’ Stargardt data
- Belite Bio upgraded to Outperform from Neutral at Mizuho